Clinical Trials · NCT05616013
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 507
- Start date
- Nov 2022
- Locations
- 26 sites, 3 countries
- Primary endpoint
- Change From Baseline in Body Weight at Week 48